One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Immunoprotein Diagnostic Testing Market

[ 英語タイトル ] Immunoprotein Diagnostic Testing Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0089334
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 117
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Abbott
- Bio-Rad Laboratories Inc.
- Calbiotech Inc.
- Diagnostic System GmbH
- Diazyme Laboratories Inc.
- Enzo Lifesciences Inc.
- F. Hoffmann-La Roche Ltd
- Randox Laboratories Ltd
- SERVA Electrophoresis GmbH
- Thermofisher Scientific Inc.

[Report Description]

The immunoprotein diagnostic testing market is expected to grow, due to the growing burden of chronic diseases and technological advancements related to the products.

- According to the Institute of Health Metrics and Evaluation, DALYS (Disability-adjusted Life Years) is a tool to measure the burden of diseases. It determines the years lost due to diseases. The countries below 20,000 per 100,000 DALYS are considered to be healthy. In 2017, the sub-Saharan African region was reported with around 80,000 DALYS per 100,000 individuals.
- Furthermore, Diagnostic System GmbH introduced a new reagent in the market in 2019. It is immunoturbidometric assay that identifies procalcitonin in the serum. Hence, these factors are expected to further boost the immunoprotein diagnostic testing market.

Key Market Trends

Endocrine Segment is Expected to Hold a Significant Market Share in the Immunoprotein Diagnostic Testing Market

The endocrine segment is expected to exhibit steady growth in the immunoprotein diagnostic testing market. The growing burden of endocrine diseases, such as diabetes, and the development of products related to immuno diagnostic testing are the factors driving the growth of the segment.

According to the Center for Disease Control and Prevention, in 2018, 1.5 million new cases were diagnosed with diabetes in the United States in people aged 18 years and above.

Furthermore, diabetic neuropathy is common consequence of diabetes. According to the study of Journal of Diabetes Research, the presence of microalbuminuria is the clinical evidence for diabetic neuropathy. Hence, the detection of microalbuminuria is very important in the diagnosis of it.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to be a dominant region, owing to the rising geriatric population and the growing burden of diseases. According to the Institute of Health Metrics and Evaluation, in 2017, the DALYS was found to be around 24,305. According to the US Census Bureau, in the United States, around 52 million of the population in 2018 were at the age of 65 or above. The older population is at high risk and likely to suffer from chronic diseases, due to its weaker metabolic and immune system. Almost a quarter of the older population is diagnosed with diabetes, and the number is expected to increase rapidly in the coming decades, according to the study of the National Institute of Diabetes and Digestive and Kidney Diseases, 2018. This emerges the need for early detection of diseases so that proper treatment can be taken. Thus, it is expected to influence positively the immunoprotein diagnostic testing market.

Competitive Landscape

Key players that are expected to be dominant in the immunoprotein diagnostic testing market are Thermofisher Scientific Inc., Enzo Lifesciences Inc., Randox Laboratories, Abbott, Bio-Rad Laboratories Inc., Abbott, SERVA Electrophoresis GmbH, F. Hoffmann-La Roche Ltd, Diazyme Laboratories Inc., and Calbiotech Inc.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Assumptions
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Diseases
4.2.2 Technological Advancements of Products
4.3 Market Restraints
4.3.1 Expenisive Techniques
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product Type
5.1.1 Instruments
5.1.2 Kits and Reagents
5.1.3 Other Product Types
5.2 By Technology
5.2.1 Chemiluminescence Assay
5.2.2 Immunofluorescence Assay
5.2.3 Immunoturbidity Assay
5.2.4 Immunoprotein Electrophoresis
5.2.5 Other Technologies
5.3 By Application
5.3.1 Infectious Disease
5.3.2 Endocrine
5.3.3 Toxicology
5.3.4 Other Applications
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East & Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbott
6.1.2 Bio-Rad Laboratories Inc.
6.1.3 Calbiotech Inc.
6.1.4 Diagnostic System GmbH
6.1.5 Diazyme Laboratories Inc.
6.1.6 Enzo Lifesciences Inc.
6.1.7 F. Hoffmann-La Roche Ltd
6.1.8 Randox Laboratories Ltd
6.1.9 SERVA Electrophoresis GmbH
6.1.10 Thermofisher Scientific Inc.




Recommended reports